<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968445</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300003221 R19-045</org_study_id>
    <nct_id>NCT03968445</nct_id>
  </id_info>
  <brief_title>Neuroinflammation After Myocardial Infarction - Imaging Substudy</brief_title>
  <official_title>Neuroinflammation After Myocardial Infarction - Imaging Substudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if positron emission tomography and magnetic resonance
      imaging (PET/MRI) with an investigational drug called [18F]DPA-714 will show inflammation in
      the brain after a heart attack. This study may help physicians and researchers better
      understand the role of brain inflammation in heart disease and develop new treatments to
      protect the brain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to measure the concentration and the regional brain
      distribution of activated brain microglia/macrophages using the PET ligand [18F]DPA-714 in
      individuals with recent AMI. The basic premise is that AMI leads to systemic inflammation
      that includes inflammation in the brain. The PET tracer [18F]DPA-714 binds to the 18 kDa
      translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the
      mitochondria of activated microglia/macrophages and provides a non-invasive measure of
      neuroinflammation. The estimates of brain TSPO binding in patients with recent AMI will be
      compared to a matched group of patients who have undergone a recent elective PCI procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2019</start_date>
  <completion_date type="Anticipated">July 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 24, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TPSO-PET measurement of neuroinflammation after acute myocardial infarction</measure>
    <time_frame>2 years</time_frame>
    <description>The regional brain concentrations of [F-18]DPA-714, a PET imaging marker of neuroinflammation, will be compared between study participants who have recently been hospitalized for acute myocardial infarction (AMI) and a control group undergoing elective percutaneous coronary interventions (PCI).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Recent Myocardial Infarction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>undergoing elective percutaneous coronary intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]DPA-714-PET/MRI</intervention_name>
    <description>[18F]DPA-714-PET/MRI</description>
    <arm_group_label>Recent Myocardial Infarction</arm_group_label>
    <arm_group_label>undergoing elective percutaneous coronary intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participation in UAB IRB protocol &quot;Neuroinflammation After Acute Myocardial
             Infarction&quot; (IRB-300002751, PI Lazar).

          2. 50 years of age or older

          3. . English speaking with at least 8th grade education

          4. High or mixed affinity binder for TSPO ligands based on genotyping for single
             nucleotide polymorphism (SNP) rs6971.

          5. Admission to UAB Hospital for ST-elevation acute myocardial infarction (AMI) and
             treatment with percutaneous coronary intervention (PCI) OR Undergoing elective
             percutaneous coronary intervention (PCI)

        Exclusion Criteria:

          1. Contraindication to MRI

          2. Pregnancy

          3. Lactation

          4. Serious medical co-morbidity that may interfere with participation

          5. Prior myocardial infarction

          6. Severe anemia

          7. Prior coronary artery bypass grafting

          8. Prior angioplasty and/or coronary artery stent placement (PCI group only)

          9. History of traumatic head injury defined by a loss of consciousness â‰¥30 minutes or
             seizure at the time of injury

         10. Diagnosis of major depression

         11. Diagnosis of dementia

         12. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan McConathy, MD, PhD</last_name>
    <phone>205-996-7115</phone>
    <email>jmcconathy@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Riddle, BS RT</last_name>
    <phone>205-934-6504</phone>
    <email>ariddle@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan McConathy, MD</last_name>
      <phone>205-996-7115</phone>
      <email>jmcconathy@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan McConathy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bag Asim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bhambhvani Pradeep, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Choudhary Gagandeep, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geldmacher David, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lapi Suzanne, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffers Charlotte Denise, RPh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natelson Marissa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberson Erik, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jonathan E McConathy</investigator_full_name>
    <investigator_title>M.D. P.h.D., Director for the Division Molecular Imaging and Therapeutics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

